Skip to main content
ANVS
NYSE Life Sciences

Director Michael Hoffman Makes Substantial $1.5M Open Market Purchase in Annovis Bio

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$2.27
Mkt Cap
$64.65M
52W Low
$1.11
52W High
$5.5
52W Position info
105% above low
Off High info
59% below high
Rel. Volume info
2.1× avg
Market data snapshot near publication time

ANVS has more than doubled off its 52-week low of $1.11 on elevated volume (2.1× avg).

Summary

Annovis Bio Director Michael Hoffman purchased $1.5 million in company stock, a significant investment signaling strong confidence despite the company's disclosed financial distress and delisting notice.


Key Events · Ownership and Investor Activity · ANVS

  • Director Makes Large Open Market Purchase

    Michael Hoffman, a Director at Annovis Bio, acquired 713,800 shares of common stock for a total of $1,498,980 in an open market transaction on April 2, 2026.

  • Significant Vote of Confidence Amidst Challenges

    This substantial purchase signals strong insider conviction despite the company's recent disclosure of "going concern" issues and a NYSE delisting notice.

  • Follows Recent Patent Grant

    The transaction occurred the day after Annovis Bio announced securing a U.S. patent for its lead drug candidate, buntanetap, potentially influencing the director's investment decision.


Analysis · ANVS · Life Sciences

Director Michael Hoffman's significant open market purchase of nearly $1.5 million in Annovis Bio common stock represents a strong vote of confidence, especially given the company's recent disclosure of "going concern" issues and a NYSE delisting notice. This substantial investment, representing over 2% of the company's market capitalization, comes shortly after the company announced a new U.S. patent for its lead drug candidate, buntanetap. The purchase by a director, despite recent leadership changes (CFO departure), suggests a belief in the company's long-term prospects and the potential of its drug pipeline amidst financial challenges.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 52.8% of the 195 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.69%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ANVS was trading at $2.27 on NYSE in the Life Sciences sector, with a market capitalization of approximately $64.7M. The 52-week trading range was $1.11 to $5.50. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ANVS - Latest Insights

ANVS
Nov 13, 2026, 4:24 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.940
Real-time Price: $0.9217 info
Change: -$0.0183 (-2%) info
Market Cap: $39.525M info
ANVS
Nov 06, 2026, 4:30 PM EST
Filing Type: 4
Importance Score:
8
Price at Filing: $0.8799
Real-time Price: $0.9217 info
Change: +$0.0418 (+5%) info
Market Cap: $39.525M info
ANVS
Nov 05, 2026, 8:05 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $0.8689
Real-time Price: $0.9217 info
Change: +$0.0528 (+6%) info
Market Cap: $39.525M info
ANVS
Nov 04, 2026, 5:01 PM EST
Filing Type: 424B5
Importance Score:
8
Price at Filing: $0.940
Real-time Price: $0.9217 info
Change: -$0.0183 (-2%) info
Market Cap: $39.525M info
ANVS
Nov 04, 2026, 4:07 PM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $0.8507
Real-time Price: $0.9217 info
Change: +$0.071 (+8%) info
Market Cap: $39.525M info